GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (NAS:GRTS) » Definitions » Current Ratio

Gritstone Bio (Gritstone Bio) Current Ratio : 2.00 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Gritstone Bio Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Gritstone Bio's current ratio for the quarter that ended in Mar. 2024 was 2.00.

Gritstone Bio has a current ratio of 2.00. It generally indicates good short-term financial strength.

The historical rank and industry rank for Gritstone Bio's Current Ratio or its related term are showing as below:

GRTS' s Current Ratio Range Over the Past 10 Years
Min: 3.2   Med: 6.62   Max: 15.39
Current: 3.2

During the past 8 years, Gritstone Bio's highest Current Ratio was 15.39. The lowest was 3.20. And the median was 6.62.

GRTS's Current Ratio is ranked worse than
55.11% of 1555 companies
in the Biotechnology industry
Industry Median: 3.72 vs GRTS: 3.20

Gritstone Bio Current Ratio Historical Data

The historical data trend for Gritstone Bio's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio Current Ratio Chart

Gritstone Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 6.73 6.50 5.52 5.25 3.20

Gritstone Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.27 5.53 3.88 3.20 2.00

Competitive Comparison of Gritstone Bio's Current Ratio

For the Biotechnology subindustry, Gritstone Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gritstone Bio's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gritstone Bio's Current Ratio distribution charts can be found below:

* The bar in red indicates where Gritstone Bio's Current Ratio falls into.



Gritstone Bio Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Gritstone Bio's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=87.435/27.339
=3.20

Gritstone Bio's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=51.853/25.87
=2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gritstone Bio  (NAS:GRTS) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Gritstone Bio Current Ratio Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gritstone Bio (Gritstone Bio) Business Description

Traded in Other Exchanges
Address
5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.
Executives
Lawrence Corey director C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi director C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher director C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Vassiliki Economides officer: See Remarks C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Erin Jones officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
James Cho officer: Chief Accounting Officer C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rahsaan Thompson officer: EVP and General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Vijay Yabannavar officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Nicholas Simon director 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142